GlassScriptPhysician profile
Amarpreet S Brar
NPI 1356361109
$16,918.90
in general payments reported to CMS, 2019-2025
30 companies · $3,304 in 2025
The $3,304 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $719 · 2021: $1,827 · 2022: $2,340 · 2023: $3,959 · 2024: $3,811 · 2025: $3,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,756 · Consulting Fee: $2,500 · Travel and Lodging: $1,442 · Long Term Medical Supply Or Device Loan: $300 · Honoraria: $38.86 · Entertainment: $38.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,755.96 |
| Consulting Fee | $2,500.00 |
| Travel and Lodging | $1,441.56 |
| Long Term Medical Supply Or Device Loan | $300.00 |
| Honoraria | $38.86 |
| Entertainment | $38.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $8,385.82 | 2019-2025 | Lensx, Clareon, Argos |
| Rxsight INC | $3,216.48 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $1,200.08 | 2019-2025 | Idosetr, Istent Infinite |
| Bausch & Lomb Americas INC. | $1,124.69 | 2022-2025 | Envista Envy Iol, Stellaris, Vyzulta |
| Abbvie INC. | $670.52 | 2022-2025 | Durysta, Vuity, Lumigan |
| Ocular Therapeutix, INC. | $554.04 | 2019-2025 | Dextenza |
| Sight Sciences, INC. | $254.69 | 2021-2024 | Tearcare System, Omni Surgical System |
| Horizon Therapeutics Plc | $175.11 | 2021-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $169.25 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $152.16 | 2024-2025 | Tyrvaya |
| Ivantis, INC | $147.53 | 2021 | |
| Allergan, INC. | $133.01 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $105.02 | 2019-2025 | Veritas Vision System, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $93.33 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $88.17 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $76.77 | 2025 | |
| Dompe US, INC. | $59.45 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $46.22 | 2019-2021 | |
| Optos, INC. | $38.53 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $37.62 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $32.24 | 2023 | Acthar |
| Dutch Ophthalmic, USA | $26.64 | 2025 | Tissueblue, Eva, Combined Machine |
| Shire North American Group INC | $23.43 | 2019 | |
| Amgen INC. | $21.75 | 2025 | Tepezza |
| Harrow Eye, LLC | $21.28 | 2025 | Vevye |
| Thea Pharma INC. | $19.01 | 2024 | Iyuzeh |
| Beaver-Visitec International, INC. | $16.47 | 2023 | |
| Kala Pharmaceuticals, INC. | $14.93 | 2021 | |
| Biotissue Holdings INC. | $14.66 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amarpreet Brar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.